Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis
eJHaem · 2026-10 · 7 (5)
DOI: 10.1002/jha2.70407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift eJHaem, online erschienen am 05.10.2026. Verfasst von Anfal Khan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Saidu Medical College Swat Pakistan. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available evidence remains limited and heterogeneous. We performed a systematic review and meta‐analysis to evaluate its efficacy and safety.
Methods
A systematic search of PubMed, Google Scholar, Semantic Scholar, ClinicalTrials.gov and the Cochrane Library was conducted from inception to 31 August 2025. Twenty‐three prospective and retrospective studies involving 547 patients were included. Random‐effects meta‐analyses of proportions were performed to estimate pooled 12‐month overall survival (OS), 12‐month progression‐free survival (PFS), complete response (CR), cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS).
Results
The pooled 12‐month OS and PFS rates were 64.5% (95% CI, 49.0%–76.0%) and 51.0% (95% CI, 35.0%–68.0%), respectively. The pooled CR rate was 52% in PCNSL and 40% in SCNSL. CRS occurred in 76% of patients with PCNSL and 77% with SCNSL, while ICANS occurred in 50% and 46%, respectively. Most adverse events were manageable with standard supportive care.
Conclusions
CD19‐directed CAR T‐cell therapy is associated with encouraging survival and response outcomes and an acceptable safety profile in relapsed or refractory PCNSL and SCNSL. However, the available evidence is predominantly retrospective with clinical heterogeneity and relatively short follow‐up, underscoring the need for larger prospective studies with longer follow‐up. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Saidu Medical College Swat Pakistan.
- United Medical and Dental College Karachi Pakistan.
- Rawalpindi Medical University Rawalpindi Pakistan.
- Chief, Department of Internal Medicine Nasrat Bashir Curative Hospital Kandahar Afghanistan.
- Ziauddin University Karachi Pakistan.
- Jinnah Sindh Medical University Karachi Pakistan.
Zitieren
APA
Khan, A., Malik, A. A., Kareem, W., Idrees, M., Kamil, K. A., Irshad, K., Baig, Z. M., Yahya, A., Qureshi, W., Ahmad, M., & Bilanda, B. (2026). Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis. eJHaem, 7(5). https://doi.org/10.1002/jha2.70407
Vancouver
Khan A, Malik AA, Kareem W, Idrees M, Kamil KA, Irshad K, et al. Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis. eJHaem. 2026;7(5). doi:10.1002/jha2.70407
BibTeX
@article{Khan2026,
author = {Khan, Anfal and Malik, Aleena Amir and Kareem, Waqas and Idrees, Mohammad and Kamil, Kamil Ahmad and Irshad, Kinza and Baig, Zainab Mehmood and Yahya, Anosha and Qureshi, Wardah and Ahmad, Manzoor and Bilanda, Bakht},
title = {Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/jha2.70407}
}
EUVIMED